Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.
Jean Jacques Grob
Consultant or Advisory Role - Roche
Honoraria - Roche
Rainer Kunstfeld
Consultant or Advisory Role - Roche
Honoraria - Roche
Brigitte Dreno
Consultant or Advisory Role - Roche
Thomas Jouary
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Other Remuneration - Roche
Laurent Mortier
Consultant or Advisory Role - Roche/Genentech
Nicole Basset-Seguin
Consultant or Advisory Role - Roche
Honoraria - Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech
Johan Hansson
Research Funding - Roche
Lada Mitchell
Employment or Leadership Position - Roche
Michal Starnawski
Employment or Leadership Position - Roche
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche